{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"GOG GYN-LIVE","title":"GOG-3110/ENGOT-EN28 Bluestar-Endometrial01 Clinical Trial Update","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/9799441b\"></iframe>","width":"100%","height":180,"duration":885,"description":"Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4 Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy\nThis is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 selected advanced/metastatic EC that progressed following platinum based chemotherapy and anti-PD-1/anti-PD-L1 therapy.","thumbnail_url":"https://img.transistorcdn.com/sOkTa17JG9Jf3iHl-IIgq5qJ9hebEILR6MMnOR6A7sE/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9iY2Iw/YTI3MWRhNmFhZGEy/ZDQxNTRkZWEwYTYw/MzY2Ny5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}